Perrigo Co PLC: Investor Litigation and Market Context

Perrigo Co PLC (ticker PRGO), listed on the Frankfurt Stock Exchange and traded in the United States, is a health‑care company that produces over‑the‑counter (OTC) drugs, infant formulas, branded OTC products, and generic pharmaceuticals. As of 14 December 2025 the share price closed at EUR 11.08, below the 52‑week low of EUR 10.505. The company’s market capitalization is approximately EUR 1.55 billion, and the price‑earnings ratio stands at 8.06.

Litigation Landscape

On 15 December 2025, multiple law firms announced the filing of a class‑action lawsuit on behalf of investors who purchased Perrigo shares between 27 February 2023 and 4 November 2025. The filings were coordinated by the Portnoy Law Firm, with additional support from Rosen, Levi & Korsinsky, and Bronstein, Gewirtz & Grossman LLC. The plaintiffs allege that Perrigo engaged in securities‑law violations that misled investors and caused financial losses.

The lawsuits were launched ahead of a key deadline of January 16, 2026 for investors to join the action. Several legal counsel firms, including Robbins Geller Rudman & Dowd LLP and Pomerantz LLP, urged shareholders to consider legal representation. The filings were disseminated through press releases on Globenewswire and PR‑Inside, with copy‑edited summaries distributed to investors by 16 December 2025.

Investor Guidance

Legal advisers have advised shareholders to act promptly to preserve their rights. The deadline for joining the lawsuit is imminent, and investors who purchased shares within the specified period are eligible to participate. Shareholders are encouraged to consult with the named law firms or seek independent legal counsel to evaluate potential claims and recovery mechanisms.

Market Reaction

In the days surrounding the announcements, analyst coverage remained mixed. JP Morgan lowered its price target for PRGO to USD 18 and maintained a neutral recommendation. The adjustment reflects concerns over potential litigation costs, regulatory scrutiny, and the impact on shareholder value. The market has not yet responded with significant volatility, but the upcoming court filings and deadlines are likely to influence investor sentiment.

Contextual Performance

Historically, Perrigo shares have experienced considerable price swings. For instance, a 3‑year retrospective analysis published on 16 December 2022 highlighted potential losses for investors who entered the market at that time. While the company’s 52‑week high reached EUR 29.31 in March 2025, the current trading price remains below that peak.

Summary

  • Class action filed on 15 December 2025 covering shares purchased between 27 Feb 2023 and 4 Nov 2025.
  • Deadline for participation: 16 January 2026.
  • Legal counsel: Portnoy, Rosen, Levi & Korsinsky, Bronstein, Gewirtz & Grossman, Robbins Geller Rudman & Dowd, Pomerantz.
  • Analyst view: JP Morgan lowered target to USD 18, neutral stance.
  • Stock status: EUR 11.08 (close 14 Dec 2025), 52‑week low EUR 10.505.

Shareholders should monitor the legal developments closely and consider timely engagement with counsel to protect potential claims.